Published in Clinical Oncology Week, October 29th, 2007
"Phase 2 studies have assessed the activity of intravesical gemcitabine on a marker lesion in intermediate-risk superficial bladder cancers (SBCs), showing complete responses in up to 60% of cases. Few attempts have been made to test the activity of intravesical gemcitabine in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.